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Abstract To minimize the clinical burden associated
with multiple sclerosis (MS), early control of focal and
diffuse CNS disease activity is a treatment priority. A post
hoc analysis was conducted to evaluate the onset of effi-
cacy of fingolimod treatment in patients with relapsing MS.
Data from patients who received fingolimod 0.5 mg or
placebo during either of two 24-month, double-blind, ran-
domized, parallel-group clinical trials (FREEDOMS and
FREEDOMS II) were pooled for analysis. Efficacy out-
comes were: time to first confirmed relapse; annualized
relapse rate (ARR); proportions of patients free from T1
gadolinium-enhancing lesions or new/newly enlarged T2
lesions; percentage brain volume loss (BVL); and change
in Multiple Sclerosis Functional Composite (MSFC)
z-score from baseline to 6 months. An early benefit was
seen with fingolimod (N = 783) vs. placebo (N = 773) for
ARR at both 3 and 6 months (3 months, 0.32 vs. 0.52,
p = 0.0015; 6 months, 0.21 vs. 0.45, p\ 0.0001). Time to
first relapse was also delayed with fingolimod vs. placebo
from day 48 onwards. At 6 months, more patients in the
fingolimod group than in the placebo group were free from
new MRI activity (65.3 vs. 40.5 %, p\ 0.0001) and had
less BVL (37.1 % reduction vs. placebo, p\ 0.001).
MSFC z-score favored fingolimod over placebo at
6 months, with improvements noted in 9-Hole Peg Test
and Paced Auditory Serial Addition Test scores.
Improvements in outcomes related to relapses, MRI, dis-
ability, cognition, and BVL occurred within 6 months of
treatment initiation with fingolimod.
Keywords Brain volume loss  Cognition  Early
treatment  Fingolimod  MRI  Multiple sclerosis  Relapse
Introduction
Early reduction of disease activity is an important thera-
peutic goal for patients with multiple sclerosis (MS) to
minimize neuro-axonal damage, prevent irreversible
accumulation of disability and prolong survival [1, 10].
The initial phase 2 study of oral fingolimod (FTY720;
Gilenya, Novartis Pharma AG, Basel, Switzerland) in
patients with relapsing MS showed reductions in inflam-
matory activity evident on magnetic resonance imaging
(MRI) as early as 2 months into treatment; reductions in
annualized relapse rate (ARR) were reported within
6 months, albeit using higher doses of fingolimod than the
approved, once-daily 0.5 mg dose [12]. At this lower dose,
fingolimod significantly reduced clinical and MRI disease
activity compared with interferon b-1a i.m. [5] and placebo
[2, 15] in phase 3 studies over 12 and 24 months, with
effects on MRI outcomes evident within 6 months. Brain
Electronic supplementary material The online version of this
article (doi:10.1007/s00415-015-7978-y) contains supplementary
material, which is available to authorized users.
& Ludwig Kappos
lkappos@uhbs.ch
1 Neurology, Departments of Medicine, Clinical Research,
Biomedicine and Biomedical Engineering, University
Hospital, Petersgraben 4, 4031 Basel, Switzerland
2 Medical Image Analysis Center, University Hospital Basel,
Basel, Switzerland
3 Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA
4 Novartis Pharma AG, Basel, Switzerland
5 Corinne Goldsmith Dickinson Center for Multiple Sclerosis,
Icahn School of Medicine at Mount Sinai, New York, NY,
USA
123
J Neurol (2016) 263:354–360
DOI 10.1007/s00415-015-7978-y
volume loss (BVL), which can occur in the earliest stages
of MS as a consequence of focal inflammatory and diffuse
damage to the central nervous system (CNS) [1], was also
significantly reduced by fingolimod in the first 6 months of
therapy [12, 17]. Within the same time frame, fingolimod
reduced the conversion of baseline T1 gadolinium (Gd)-
enhancing MRI lesions into black holes, indicative of
decreased permanent damage in the brain [16].
Using a pooled population from the two placebo-con-
trolled, phase 3 studies (FTY720 Research Evaluating
Effects of Daily Oral Therapy in MS [FREEDOMS;
ClinicalTrials.gov number, NCT00289978] and FREE-
DOMS II [ClinicalTrials.gov number, NCT00355134]),
clinical and MRI measures were assessed to establish the
timing of the onset of treatment effects during the first
6 months of fingolimod therapy.
Materials and methods
Patients and study design
The study design and overall results for FREEDOMS and
FREEDOMS II have been reported previously [2, 15]. In
brief, FREEDOMS and FREEDOMS II were 24-month,
double-blind, randomized, parallel-group clinical trials
comparing the efficacy and safety of two oral doses of
fingolimod (0.5 and 1.25 mg/day) with placebo in patients
18–55 years of age with active relapsing–remitting MS
(RRMS).
In both trials, standardized MRI scans were performed at
screening, 6, 12, and 24 months after initiation of treat-
ment. Multiple Sclerosis Functional Composite (MSFC)
z-scores were determined at baseline and at 6-month
intervals thereafter. The same definition of a confirmed
relapse was applied in both FREEDOMS and FREEDOMS
II: symptoms were required to be accompanied by an
increase of at least half a point in the Expanded Disability
Status Scale (EDSS) score, or of one point in the score for
two different functional systems of the EDSS, or of two
points in the score for one of the functional systems (ex-
cluding bowel, bladder, or cerebral functional systems).
Statistical analyses
Pooled data from FREEDOMS and FREEDOMS II were
analyzed post hoc for treatment differences between the
fingolimod 0.5 mg and placebo groups in relapse and MRI
endpoints within the first 6 months. The time to first con-
firmed relapse was estimated using the Kaplan–Meier
method. The effect of fingolimod and placebo on time to
first relapse was compared using a log-rank test. ARRs in
the two treatment arms were compared using a Poisson
regression model, adjusted for treatment, study, number of
relapses in the 2 years before enrollment, and core baseline
EDSS score; log(time in study) was the offset variable.
The proportions of patients free from T1 Gd-enhancing
lesions or new/newly enlarged T2 lesions were analyzed
using a logistic regression model adjusted for treatment,
study, pooled country, and corresponding MRI baseline
measurement. Percentage brain volume change (PBVC)
from baseline [determined using Structural Image Evalua-
tion using Normalization of Atrophy (SIENA) methodology
as a] measure of BVL was compared between treatment
arms using rank analysis of covariance (ANCOVA; adjusted
for treatment, study, pooled country, and baseline normal-
ized brain volume). Change from baseline in MSFC z-score
to 6 months was compared between treatment arms using
rank ANCOVA (adjusted for treatment, study, the corre-
sponding baseline value, and age). Analyses were conducted




Of the 2355 patients in the pooled population of FREE-
DOMS and FREEDOMS II, 783 were randomized to
receive fingolimod 0.5 mg and 773 were randomized to the
placebo group. Baseline demographic and clinical charac-
teristics of patients in the two individual studies have been
reported previously [2, 15] and were generally similar. The
pooled study population was consistent with a typical
population of patients with active RRMS (Online Resource
1).
Early effects of treatment on clinical outcomes
At 3 months, fingolimod reduced ARR compared with
placebo (38.5 % reduction, p = 0.0015); this treatment
effect was maintained over months 3–6 (53.3 % reduction,
p\ 0.0001; Table 1). The difference in time to first con-
firmed relapse between the fingolimod 0.5 mg and placebo
groups reached significance (p B 0.05) at day 48 and
remained significant thereafter (Fig. 1). Based on Kaplan–
Meier estimates, the proportion of patients free from con-
firmed relapses was significantly higher with fingolimod
than with placebo at 3 and 6 months, equating to reductions
of 35.5 and 42.8 %, respectively, in the risk of having
confirmed relapse (Table 1). The change from baseline to
6 months in MSFC z-score favored fingolimod over pla-
cebo [mean (median): -0.01 (0.02) vs. -0.04 (-0.04),
respectively; p\ 0.0001; Table 1]. Similarly, compared
with placebo, fingolimod improved the outcome for two of
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the three individual MSFC subscales [Paced Auditory
Serial Addition Test (PASAT) and 9-Hole Peg Test]
(Table 1).
Early effects of treatment on MRI outcomes
Compared with placebo, fingolimod reduced the number
of Gd-enhancing T1 lesions by 83.8 % and new/newly
enlarged T2 lesions by 72.6 % over 6 months (first on-
study MRI) (Table 2). Similarly, a significantly greater
proportion of patients was free from Gd-enhancing T1
lesions (42.0 % increase) and also free from new/newly
enlarged T2 lesions (63.3 % increase) at 6 months in the
fingolimod group than in the placebo group (Table 2). At
6 months, the proportion of patients free from any new
MRI activity was significantly higher in the fingolimod
group than in the placebo group (61.2 % increase;
Table 2). A significant difference in the PBVC was seen
between the fingolimod group and the placebo group at
6 months, with 37.1 % less BVL evident in the fingolimod
group (Table 2).
Discussion
In patients with active MS, early initiation of, and
adherence to, a disease-modifying therapy (DMT) that


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1 Time to first confirmed MS relapse in the pooled FREEDOMS
and FREEDOMS II population (intent-to-treat populations). A delay
in the time to first confirmed MS relapse was first observed on day 48
(p B 0.05; log-rank test) in the pooled FREEDOMS and FREEDOMS
II population
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acute inflammation and its neuropathological sequelae, and
also to prevent subsequent disease activity. Furthermore,
treating patients with MS early in the disease course with
agents that not only target relapses but also subclinical,
silent disease (including BVL) could provide long-term
benefits. The current analyses of pooled data from the
phase 3, placebo-controlled studies indicate that the onset
of action of fingolimod on relapses, MRI lesions, BVL,
upper extremity function, and cognition commenced early,
within 3–6 months of treatment initiation. The early effect
on relapses and MRI lesions is consistent with the results
obtained in the phase 2 study: once-daily fingolimod 1.25
and 5.0 mg increased the proportion of patients who were
relapse-free over 6 months and free from Gd-enhancing T1
lesions as early as 2 months after therapy initiation. In
FIRST (Fingolimod Initiation and caRdiac Safety Trial), an
effect on relapses was seen within 2–4 months of starting
therapy with the approved dose of 0.5 mg fingolimod,
irrespective of patients’ previous treatment experience [6,
7, 12].
Among the most salient evidence of an early treatment
effect of fingolimod was the reduction in the rate of BVL
within the first 6 months, seen here with the pooled pop-
ulation and reported previously in the individual studies [2,
15, 17]. This effect may be related to preclinical and
in vitro findings of direct effects of fingolimod on the CNS
[3], and is further substantiated by the effect of fingolimod,
in decreasing the evolution of inflammatory lesions into
black holes, as seen at 6 months in the FREEDOMS study
[16].
Early treatment effects have been reported for other
approved DMTs, with improvements in relapse rates at
3 months with natalizumab and dimethyl fumarate (DMF),
in a composite measure of MRI lesions at week 4 with
Table 2 MRI measures of disease activity in the first 6 months after initiation of fingolimod therapy in the pooled FREEDOMS and FREE-
DOMS II population
Fingolimod 0.5 mg N = 783 Placebo N = 773
Number of Gd-enhancing T1 lesions 6 months
Number of patients 726 698
Mean ± SD 0.2 ± 0.9 1.2 ± 3.2
Median (range) 0.0 (0–13) 0.0 (0–43)
Number (%) of patients free from Gd-enhancing T1 lesions 644 (88.6) 438 (62.4)
p value vs. placeboa \0.0001
Number of new/newly enlarged T2 lesions Months 0–6
Number of patients 729 721
Mean ± SD 0.9 ± 2.3 3.3 ± 7.0
Median (range) 0.0 (0–28) 1.0 (0–96)
Number (%) of patients free from new/newly enlarged T2 lesions 478 (65.3) 289 (40.0)
p value vs. placebob \0.0001
Patients free from new MRI activity At 6 months
Number (%) of patients free from new MRI activityc 475 (65.3) 284 (40.5)
p value vs. placeboa \0.0001
Brain volume loss At 6 months
Number of patients 714 709
Mean PBVC from baseline -0.23 -0.36
Reduction vs. placebo (%) 37.1
p value vs. placebod \0.001
For MRI data, percentages were calculated using the number of patients with an evaluable MRI scan as denominator: 727 and 702 (Gd-enhancing
T1 lesions) and 732 and 723 (new/newly enlarged T2 lesions) patients in the fingolimod 0.5 mg pooled group and placebo pooled group,
respectively. For patients free from new MRI activity, the denominator was the same as for the fingolimod 0.5 mg pooled group. The means and
medians were calculated on the basis of all images, not just those showing lesions
Gd gadolinium, MRI magnetic resonance imaging, PBVC percentage brain volume change
a p value calculated using a logistic regression model adjusted for treatment, study, pooled country, and baseline number of Gd-enhancing T1
lesions
b p value calculated using a logistic regression model adjusted for treatment, study, and pooled country
c Patients free from new MRI activity are patients who have no Gd-enhancing T1 lesions and no new/newly enlarged T2 lesions
d p values are from rank analysis of covariance adjusted for treatment, study, pooled country, and baseline normalized brain volume, and indicate
two-sided significance at the 0.05 level
358 J Neurol (2016) 263:354–360
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interferon b-1a, and in overall disease activity at 6 months
(clinical and MRI composite) with DMF [9, 11, 13, 14].
However, none of these treatments had an effect at
6 months on a clinical measure of disability or on BVL [9,
11, 13, 14]; any reported effects on brain atrophy were
delayed beyond the first year of therapy, this delay usually
being attributed to ‘‘pseudoatrophy’’ caused by an anti-
inflammatory effect of DMTs occurring within the first
year of therapy [8]. Notably, the significant reduction in
BVL observed with fingolimod at 6 months was achieved
despite a pronounced and early reduction in inflammatory
activity. Taken together, the effects of fingolimod on BVL,
deep grey matter [18] and MSFC outcomes, including the
PASAT cognition subscale score [4], suggest that fin-
golimod may also modify correlates of diffuse CNS dam-
age early after the initiation of treatment.
The limitations of these post hoc analyses include the lack
of adjustment for multiplicity and, owing to the low number
of relapses up to month 6 (compared up to months 12 and
24), the use of a Poisson model for ARR analysis rather than
the negative binomial model used in the pivotal study anal-
ysis; however, these limitations should be weighed against
the large number of patients in the pooled population. In
addition, it should be recognized that the PASAT is not a
global measure of cognitive function, and suffers from
marked practice effects [19], although in FREEDOMS and
FREEDOMS II, the impact of practice effects should have
been reduced by patients undertaking three PASAT training
sessions during the pre-treatment period.
Overall, the analyses reported here indicate that, within
6 months of initiation, treatment benefits of fingolimod
were evident on key measures of focal and diffuse disease
in relapsing MS, i.e., relapses, MRI lesions and BVL, as
well as on elements of disability and cognitive function.
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